Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of lersivirine for the treatment of HIV-1 infection
2010-020860-39Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lersivirine in Human immunodeficiency virus infection type 1, sponsored by Pfizer. Primary endpoint: Primary safety and tolerability. Started Aug 2010; status: terminated.
02
Drugs
lersivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-020860-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020860-39.